Skip to Content
A29 / P29
NCODA Oncology and Hematology Meeting Abstracts | Volume 1 | Supplement 1
Publication Date: June 15, 2026

Prostate-specific antigen response with darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer in ARANOTE

Authors:

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO1,2, on behalf of Fred Saad, MD3; Kunhi Parambath Haresh, MD4; Neal Shore, MD, FACS5; Egils Vjaters, MD6; David Olmos, MD, PhD7; Natasha Littleton, MSc8; Isabella Testa, MD9; Shankar Srinivasan, PhD10; Frank Verholen, MD11; Alberto Briganti, MD, PhD12

Organization / Company:

1Minnesota Oncology, St. Paul, Minnesota, USA; 2Mayo Clinic College of Medicine, Rochester, Minnesota, USA; 3Department of Surgery/Urology, Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal, Quebec, Canada; 4All India Institute of Medical Sciences, New Delhi, India; 5Carolina Urologic Research Center and AUC Urology Specialists, Myrtle Beach, South Carolina, USA; 6P. Stradinš Clinical University Hospital, Riga, Latvia; 7Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain; 8Bayer Ltd, Dublin, Ireland; 9Bayer S.p.A, Milan, Italy; 10Bayer Healthcare, Whippany, NJ, USA; 11Bayer Consumer Care AG, Basel, Switzerland; 12Vita-Salute University San Raffaele, Milan, Italy

NCODA Oncol Hematol Meet Abstr. 2026;1(suppl 1):abstr 29.

Background:

Patients with metastatic hormone-sensitive prostate cancer (mHSPC) were randomized 2:1 to darolutamide 600 mg twice daily + androgen-deprivation therapy (ADT) or placebo + ADT. Achievement of undetectable prostate-specific antigen (PSA) (<0.2 ng/mL) at any time was evaluated. Radiological progression-free survival (rPFS), time to metastatic castration-resistant prostate cancer (mCRPC), and time to PSA progression were evaluated in patients who did/did not achieve PSA <0.2 ng/mL, and by baseline PSA group defined as <first quartile (Q1, <4.1 ng/mL), between Q1 and median (4.1–<21.3 ng/mL), and ≥median (≥21.3 ng/mL).

 

Objectives:

Describe the PSA response with darolutamide plus ADT in patients with mHSPC in the phase 3 ARANOTE trial.

 

Methods:

Post-hoc analysis of ARANOTE correlating PSA response with outcomes overall and by baseline PSA level.

 

Results:

In 669 patients (darolutamide, 446; placebo, 223), median baseline PSA was 21.4 and 21.2 ng/mL, respectively. More patients on darolutamide achieved PSA <0.2 ng/mL at any time (62.6%) versus placebo (18.5%). Patients achieving PSA <0.2 ng/mL at any time in both groups had lower Eastern Cooperative Oncology Group (ECOG) performance status and baseline PSA values versus those who did not. Patients receiving darolutamide achieving PSA <0.2 ng/mL versus those who did not have lower risk of radiological progression or death (81%, hazard ratio [HR] 0.19; 95% confidence interval [CI] 0.13–0.27), progression to mCRPC (84%, HR 0.16; 95% CI 0.12–0.23), and PSA progression (92%, HR 0.08; 95% CI 0.05–0.12), indicating a durable response. Regardless of baseline PSA group, more patients receiving darolutamide versus placebo achieved PSA <0.2 ng/mL at any time, with higher rates of PSA <0.2 ng/mL in patients with low baseline PSA <4.1 ng/mL: darolutamide, 87.6% versus placebo, 43.5%; 4.1 to <21.3 ng/mL: 64.8% versus 14.0%; ≥21.3 ng/mL: 50.5% versus 10.2%. Patients receiving darolutamide with low baseline PSA (<4.1 ng/mL) had a longer time to radiological progression or death, time to mCRPC, and time to PSA progression versus patients with baseline PSA ≥21.3 ng/mL; outcomes were similar for patients with baseline PSA of 4.1– <21.3 ng/mL versus ≥21.3 ng/mL. Safety with darolutamide was consistent with previous data and independent of PSA response/baseline PSA. Darolutamide showed lower rates of discontinuation due to treatment-emergent adverse events (TEAEs) versus placebo.

 

Conclusions:

More patients receiving darolutamide achieved undetectable PSA at any time versus placebo, regardless of baseline PSA. Undetectable PSA response with darolutamide correlated with clinical benefit in terms of radiological progression or death and longer times to mCRPC and PSA progression.

Funding: Bayer AG.

 

Prior Presentations:

Presented at the Annual European Association of Urology (EAU) Congress 2025, March 21-24, Madrid, Spain.

A29 / P29